活体生物疗法和微生物CDMO市场－全球产业规模、份额、趋势、机会及预测（按应用、产品、製剂类型、规模、地区和竞争格局划分，2021-2031年）

全球生物疗法产品和微生物 CDMO 市场预计将从 2025 年的 332.2 亿美元成长到 2031 年的 2,265.6 亿美元，复合年增长率为 37.71%。

生物治疗产品（LBP）利用活微生物来治疗或预防疾病，这需要具备复杂厌氧发酵和製剂能力的专业合约研发生产机构（CDMO）。由于临床研发管线不断完善，以及生物製药公司倾向于利用外部合作伙伴来应对复杂的生产流程而无需大量资本投入，该市场正在加速发展。此外，公共部门也积极推动这一领域的发展。例如，人类微生物组行动组织（Human Microbiome Action）报告称，欧盟委员会已透过「地平线欧洲」（Horizo​​n Europe）计划在2025年拨款约1亿欧元，用于促进基于微生物组的解决方案的开发和应用。

然而，缺乏统一的全球监管标准是市场发展的一大障碍。这种监管的不确定性使得标准化生产通讯协定和品管系统的建立变得复杂，阻碍了临床试验向商业化生产的顺利过渡。最终，这种不确定性会延缓新产品的核准流程，并限制创新治疗方法上市的速度。

市场驱动因素

生物治疗药物临床研发管线的快速扩张是推动市场成长的关键因素，也因此对能够扩大复杂厌氧生产规模的合约研发生产机构（CDMO）产生了显着需求。随着候选药物从早期发现阶段进入后期临床试验，对高品质、符合GMP规范的临床试验材料的需求显着增加，迫使研发人员利用外部生产资源。 Vedanta Biosciences等公司进入后期临床试验阶段，尤其反映了这种成熟趋势。该公司于2024年5月宣布，其采用口服细菌联合疗法的III期临床实验「RESTORATiVE303」已完成首例患者入组。

此外，对微生物组疗法的资本投资和资金筹措不断增加，为该领域提供了建设专业设施和开发稳定製剂技术所需的流动资金，从而推动了该领域的发展。这种资金支持不仅促进了生物技术创新，也证实了市场的商业性可行性，使企业能够在无需承担过高基础设施成本的情况下外包生产。例如，Enterobiotics公司于2024年4月宣布已获得2,700万英镑的资金筹措，用于进一步加强其临床研发管线和生产能力。此外，商业性成功也推动了策略行动，例如Seres Therapeutics公司于2024年将其VOWST资产出售给雀巢健康科学公司，获得1.55亿美元的预付款，这凸显了商业化所能实现的价值。

市场挑战

全球监管标准的缺失对全球生物治疗和微生物CDMO市场构成重大障碍。这种监管碎片化给研发企业和契约製造都带来了巨大的不确定性，迫使他们应对不同地区的各种合规要求。由于生物治疗产品依赖复杂的生物体，缺乏统一的框架使得生产製程和分析方法的检验日益困难，导致CDMO难以建立标准通讯协定。这增加了营运成本，并延长了技术转移和规模化生产的时间。

因此，这种不确定的监管环境阻碍了强大的临床研发管线向可上市治疗方法的转化。企业在从临床试验到大规模生产的过程中面临着巨大的风险，因为不一致的指导方针往往需要耗费巨资重新设计流程以满足不同的地区要求。这些瓶颈的严重性体现在创新成果难以转化为核准疗法。根据再生医学联盟（Alliance for Regenerative Medicine）2025年的数据，全球先进疗法领域约75%的收入将来自不到10种上市产品，这凸显了缺乏国际协调如何限制了广泛的商业性成功。

市场趋势

目前，市场格局正因一体化端到端服务模式的蓬勃发展而重塑。在这种模式下，合约研发生产机构（CDMO）整合了各项能力，并管理从菌株分离到商业填充和包装的整个产品生命週期。这项变革的驱动力在于简化复杂的供应链，并最大限度地降低在不同供应商之间转移敏感厌氧生物材料所带来的风险。透过提供统一的研发和生产服务，供应商可以缩短週期并确保产品的一致性。例如，Biose Industries, Inc. 在2024年12月的报告中指出，该公司生产超过600种细菌菌株，并已在全球范围内交付了1000万件成品，这充分展现了这种整合策略的规模。

同时，基因工程生物疗法（eLBPs）的出现刺激了对高度专业化生产技术的需求，这些技术用于生产具有特定治疗效果的改造生物体。与传统的联合疗法不同，这些新一代治疗方法需要先进的基因编辑工具和严格的生物安全防护通讯协定，迫使合约研发生产机构（CDMO）采用新的加工技术。这项技术进步能够精准地改造微生物组，从而针对特定的疾病路径。 Eligo Bioscience公司于2024年7月在《自然》杂誌上发表的一项突破性研究证实了其潜力，该研究展示了能够以近乎完美的效率直接对肠道环境中的细菌进行基因改造。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球活体生物治疗产品与微生物CDMO市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • （用于治疗困难梭状芽孢桿菌传染病、克隆氏症、大肠激躁症、糖尿病等）
  • 副产品（原料药、组合药物）
  • 按剂型类型（固态剂型、口服液剂型、注射剂型、其他）
  • 依生产规模（临床前生产规模、临床生产规模、商业化生产规模）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美活体生物疗法和微生物CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲活体生物疗法和微生物CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区活体生物治疗产品及微生物CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东及非洲活体生物治疗产品及微生物CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲活体生物治疗产品与微生物CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球活体生物治疗产品与微生物CDMO市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Lonza Group Ltd.
• Catalent, Inc.
• Thermo Fisher Scientific Inc.
• FUJIFILM Diosynth Biotechnologies USA, Inc.
• Samsung Biologics Co., Ltd.
• Recipharm AB
• Eurofins Scientific SE
• AGC Biologics A/S
• Boehringer Ingelheim International GmbH
• Piramal Pharma Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Live Biotherapeutics Products and Microbe CDMO Market is projected to surge from USD 33.22 Billion in 2025 to USD 226.56 Billion by 2031, expanding at a CAGR of 37.71%. Because Live Biotherapeutic Products (LBPs) utilize live microorganisms to treat or prevent diseases, they require specialized Contract Development and Manufacturing Organizations (CDMOs) equipped to handle intricate anaerobic fermentation and formulation tasks. Market acceleration is fueled by a strengthening clinical pipeline and the tendency of biopharmaceutical firms to utilize external partners to navigate manufacturing complexities without significant capital expenditure. Furthermore, public sector initiatives are actively promoting this sector; for instance, Human Microbiome Action noted in 2025 that the European Commission allocated nearly €100 million through Horizon Europe to foster development and deployment of microbiome-based solutions.

However, the absence of harmonized global regulatory standards serves as a significant obstacle to market progress. This regulatory ambiguity complicates the creation of standardized manufacturing protocols and quality control systems, which hinders the smooth transition from clinical trials to commercial-scale production. Ultimately, these uncertainties can decelerate the approval process for new products, limiting the speed at which novel therapies reach the market.

Market Driver

A primary catalyst for market growth is the swift broadening of the global live biotherapeutic clinical pipeline, creating a critical need for CDMOs that can scale complex anaerobic manufacturing operations. As candidates advance from early discovery phases to late-stage pivotal trials, the requirement for high-quality, GMP-compliant clinical trial materials increases substantially, prompting developers to engage external manufacturing resources. This maturation is highlighted by companies entering advanced testing stages, such as Vedanta Biosciences, which announced in May 2024 that it had enrolled the first patient in its pivotal Phase 3 RESTORATiVE303 study for an orally administered bacterial consortium.

Additionally, rising capital investments and funding for microbiome-based therapies are driving the sector forward by providing necessary liquidity for building specialized facilities and improving stability-enhancing formulation technologies. This financial support not only fuels biotech innovation but also confirms the commercial viability of the market, enabling firms to outsource production without bearing prohibitive infrastructure costs. For example, EnteroBiotix announced in April 2024 that it had secured £27 million to further its clinical pipeline and manufacturing capabilities. Furthermore, commercial success drives strategic activity, as seen in 2024 when Seres Therapeutics sold its VOWST assets to Nestle Health Science for an upfront payment of $155 million, highlighting the value realized upon commercialization.

Market Challenge

The lack of harmonized global regulatory standards constitutes a major hurdle for the Global Live Biotherapeutics Products and Microbe CDMO Market. This regulatory fragmentation fosters deep uncertainty for both developers and contract manufacturers, who are forced to manage differing compliance mandates across various regions. Since live biotherapeutic products rely on complex biological organisms, the lack of a unified framework makes validating manufacturing processes and analytical methods increasingly difficult, causing CDMOs to struggle with establishing standard protocols, which raises operational costs and prolongs timelines for technology transfer and scaling.

Consequently, this uncertain regulatory landscape hampers the movement of a robust clinical pipeline toward becoming marketable therapies. Companies encounter significant risks when scaling from clinical trials to mass production, as inconsistent guidelines often demand costly process re-engineering to satisfy divergent regional requirements. The severity of these bottlenecks is illustrated by the difficulty in transforming innovation into approved treatments; according to the Alliance for Regenerative Medicine in 2025, roughly 75 percent of global revenue in the advanced therapy sector came from fewer than ten commercialized products, highlighting how a lack of international alignment restricts broader commercial success.

Market Trends

The market is currently being reshaped by the proliferation of integrated end-to-end service models, where CDMOs consolidate their capabilities to manage the full product lifecycle, spanning from strain isolation to commercial fill-finish. This evolution is motivated by the necessity to simplify complex supply chains and minimize risks involved in transferring sensitive anaerobic biological materials between different vendors. By providing unified development and manufacturing services, providers can hasten timelines and ensure consistency; for instance, Biose Industrie noted in its December 2024 report that it had manufactured over 600 bacterial strains and delivered 10 million finished products worldwide, showcasing the scale of this integrated strategy.

Concurrently, the emergence of genetically engineered live biotherapeutics (eLBPs) is stimulating demand for highly specialized manufacturing technologies designed to manage modified organisms with specific therapeutic payloads. Unlike traditional consortia, these next-generation treatments necessitate advanced genetic editing tools and strict containment protocols, compelling CDMOs to implement novel processing techniques. This technical progression enables precise microbiome modification to target specific disease pathways, a potential validated by Eligo Bioscience in July 2024 when they announced a landmark study in Nature demonstrating the ability to genetically modify bacteria directly within the gut environment with near-perfect efficiency.

Key Market Players

• Lonza Group Ltd.
• Catalent, Inc.
• Thermo Fisher Scientific Inc.
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Samsung Biologics Co., Ltd.
• Recipharm AB
• Eurofins Scientific SE
• AGC Biologics A/S
• Boehringer Ingelheim International GmbH
• Piramal Pharma Limited

Report Scope

In this report, the Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Live Biotherapeutics Products and Microbe CDMO Market, By Application

• C.difficle
• Crohns disease
• IBS
• Diabetes
• Others

Live Biotherapeutics Products and Microbe CDMO Market, By Product

• APIs
• FDFs

Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation

• Solid Formulations
• Oral Liquids
• Injectables
• Others

Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation

• Preclinical Scale Operations
• Clinical Scale Operations
• Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Live Biotherapeutics Products and Microbe CDMO Market.

Available Customizations:

Global Live Biotherapeutics Products and Microbe CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Live Biotherapeutics Products and Microbe CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
  • 5.2.2. By Product (APIs, FDFs)
  • 5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
  • 5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Live Biotherapeutics Products and Microbe CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Product
  • 6.2.3. By Type of Formulation
  • 6.2.4. By Scale of Operation
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Type of Formulation
      • 6.3.1.2.4. By Scale of Operation
  • 6.3.2. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Type of Formulation
      • 6.3.2.2.4. By Scale of Operation
  • 6.3.3. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Type of Formulation
      • 6.3.3.2.4. By Scale of Operation

7. Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Product
  • 7.2.3. By Type of Formulation
  • 7.2.4. By Scale of Operation
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Type of Formulation
      • 7.3.1.2.4. By Scale of Operation
  • 7.3.2. France Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Type of Formulation
      • 7.3.2.2.4. By Scale of Operation
  • 7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Type of Formulation
      • 7.3.3.2.4. By Scale of Operation
  • 7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Type of Formulation
      • 7.3.4.2.4. By Scale of Operation
  • 7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Type of Formulation
      • 7.3.5.2.4. By Scale of Operation

8. Asia Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Product
  • 8.2.3. By Type of Formulation
  • 8.2.4. By Scale of Operation
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Type of Formulation
      • 8.3.1.2.4. By Scale of Operation
  • 8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Type of Formulation
      • 8.3.2.2.4. By Scale of Operation
  • 8.3.3. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Type of Formulation
      • 8.3.3.2.4. By Scale of Operation
  • 8.3.4. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Type of Formulation
      • 8.3.4.2.4. By Scale of Operation
  • 8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Type of Formulation
      • 8.3.5.2.4. By Scale of Operation

9. Middle East & Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Product
  • 9.2.3. By Type of Formulation
  • 9.2.4. By Scale of Operation
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Type of Formulation
      • 9.3.1.2.4. By Scale of Operation
  • 9.3.2. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Type of Formulation
      • 9.3.2.2.4. By Scale of Operation
  • 9.3.3. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Type of Formulation
      • 9.3.3.2.4. By Scale of Operation

10. South America Live Biotherapeutics Products and Microbe CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Product
  • 10.2.3. By Type of Formulation
  • 10.2.4. By Scale of Operation
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Type of Formulation
      • 10.3.1.2.4. By Scale of Operation
  • 10.3.2. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Type of Formulation
      • 10.3.2.2.4. By Scale of Operation
  • 10.3.3. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Type of Formulation
      • 10.3.3.2.4. By Scale of Operation

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Live Biotherapeutics Products and Microbe CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lonza Group Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Catalent, Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• 15.5. Samsung Biologics Co., Ltd.
• 15.6. Recipharm AB
• 15.7. Eurofins Scientific SE
• 15.8. AGC Biologics A/S
• 15.9. Boehringer Ingelheim International GmbH
• 15.10. Piramal Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer